Literature DB >> 31168666

Do complexing proteins provide mechanical protection for botulinum neurotoxins?

Dirk Dressler1, Lizhen Pan2,3, Fereshte Adib Saberi2, Hans Bigalke4.   

Abstract

Botulinum toxin (BT) consists of botulinum neurotoxin and complexing proteins (CPs). CPs might provide mechanical protection for botulinum neurotoxin. As incobotulinumtoxinA (INCO, Xeomin®) does not contain CPs, we wanted to compare its mechanical stability to that of onabotulinumtoxinA (ONA, Botox®) containing CPs. For this, ONA and INCO were reconstituted without mechanical stress (NS) and with mechanical stress (WS) generated by a recently introduced stress test. Potencies were then measured by the paralysis times (PTs) in the mouse diaphragm assay. ONA-PT was 75.8 ± 10.3 min (n = 6) under NS and 116.7 ± 29.8 min (n = 6) under WS (two-tailed t test, p = 0.002). Mechanical stress increased the ONA-PT by 35.0% on the Growth Percentage Index. INCO-PT was 66.0 ± 7.0 min for NS and 76.0 ± 1.0 min for WS (t test, p = 0.129). Mechanical stress increased the INCO-PT by 13.2% on the Growth Percentage Index. Our data show that mechanical stress inactivates a CP-containing BT drug, but not a CP-free BT drug. We conclude that CPs do not provide protection against mechanical stress, supporting the view that CPs are not necessary for therapeutic purposes.

Entities:  

Keywords:  Botulinum toxin; Complexing proteins; Hemidiaphragm assay; Mechanical stability

Year:  2019        PMID: 31168666     DOI: 10.1007/s00702-019-02023-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  17 in total

1.  Observations on the isolated phrenic nerve diaphragm preparation of the rat.

Authors:  E BULBRING
Journal:  Br J Pharmacol Chemother       Date:  1946-03

2.  Botulinum toxin A: is it really that fragile a molecule?

Authors:  Debraj Shome; Akshay G Nair; Rinky Kapoor; Vandana Jain
Journal:  Dermatol Surg       Date:  2010-12       Impact factor: 3.398

Review 3.  Transport of bacterial toxins into target cells: pathways followed by cholera toxin and botulinum progenitor toxin.

Authors:  Yukako Fujinaga
Journal:  J Biochem       Date:  2006-08       Impact factor: 3.387

Review 4.  Using translational medicine to understand clinical differences between botulinum toxin formulations.

Authors:  K R Aoki; D Ranoux; J Wissel
Journal:  Eur J Neurol       Date:  2006-12       Impact factor: 6.089

Review 5.  Diffusion characteristics of botulinum neurotoxin products and their clinical significance in cosmetic applications.

Authors:  Ada Trindade de Almeida; Koenraad De Boulle
Journal:  J Cosmet Laser Ther       Date:  2007       Impact factor: 2.247

6.  Confusion about diffusion and the art of misinterpreting data when comparing different botulinum toxins used in aesthetic applications.

Authors:  Andy Pickett; Stephen Dodd; Berthold Rzany
Journal:  J Cosmet Laser Ther       Date:  2008-09       Impact factor: 2.247

Review 7.  Clostridium botulinum and its neurotoxins: a metabolic and cellular perspective.

Authors:  E A Johnson; M Bradshaw
Journal:  Toxicon       Date:  2001-11       Impact factor: 3.033

8.  Studies on the dissociation of botulinum neurotoxin type A complexes.

Authors:  Karl-Heinz Eisele; Klaus Fink; Martin Vey; Harold V Taylor
Journal:  Toxicon       Date:  2010-12-30       Impact factor: 3.033

9.  Disruption of the epithelial barrier by botulinum haemagglutinin (HA) proteins - differences in cell tropism and the mechanism of action between HA proteins of types A or B, and HA proteins of type C.

Authors:  Yingji Jin; Yuki Takegahara; Yo Sugawara; Takuhiro Matsumura; Yukako Fujinaga
Journal:  Microbiology       Date:  2009-01       Impact factor: 2.777

10.  Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: time course of tissue distribution.

Authors:  Diane D-S Tang-Liu; K Roger Aoki; J Oliver Dolly; Anton de Paiva; Tara L Houchen; Leslie F Chasseaud; Colin Webber
Journal:  Toxicon       Date:  2003-10       Impact factor: 3.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.